Bioretec Oy

Bioretec Oy has a market capitalization of EUR 16.91 million and a price-to-book ratio of 1.73, indicating a premium valuation relative to its book value. The company holds EUR 4.13 million in cash and equivalents, with total liabilities of EUR 1.92 million, resulting in a low debt-to-equity ratio of 0.04 and a strong current ratio of 5.18, suggesting robust short-term liquidity. The company reported a net loss of EUR 9.48 million for the latest period, with an operating loss of EUR 8.69 million. Return on equity (ROE) is negative at -9.71%, and return on assets (ROA) is also negative at -8.12%, indicating poor profitability relative to its equity and asset base. The enterprise value to revenue (EV/Revenue) is 3.75, and the EV/EBITDA is negative at -1.52, reflecting the company's current unprofitable state and high valuation multiple. Bioretec Oy's revenue is concentrated in a single business segment focused on bioresorbable orthopedic implants. The company operates primarily in Finland, with a subsidiary in Germany, and its products are distributed globally. There is no disclosed geographic revenue breakdown, but the company's operations are centered in Europe. The company's revenue for the latest period was EUR 3.52 million. Analysts have not provided growth estimates, and the company has not disclosed future revenue guidance. The company's operating cash flow is negative at EUR -9.76 million, and free cash flow is also negative at EUR -9.86 million, indicating that the company is not generating positive cash from operations. Bioretec Oy faces low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low debt load and a strong cash position, but its negative operating and net income suggest ongoing financial challenges. No dilutive events have been identified in recent filings, and the company has not issued additional shares recently. No recent filings or transcripts have been disclosed that provide insight into the company's strategic direction or operational performance. The company's financial results and valuation metrics suggest a high-risk, high-growth profile, but there is limited public commentary or analyst coverage to support further analysis.